In summary, these data collectively suggest inhibitors of HIPK2, either inhibiting the kinase activity or its interaction with downstream effectors such as Smad3, would be therapeutically effective against renal fibrosis in CKD. The gene discussed is HIPK2; the disease is renal fibrosis.